Medicine Price Transparency Under Scrutiny At Next World Health Assembly
Executive Summary
At the forthcoming 72nd World Health Assembly, delegates will discuss a resolution calling for greater transparency on medicine prices.
You may also be interested in...
Pricing And R&D Transparency Proposals Face Pushback At WHA
A draft resolution on the transparency of medicine prices and R&D costs is being discussed this week by World Health Organization members, but the pharmaceutical industry says some measures will be damaging for medicines access.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.